STOCK TITAN

Amgen Inc - AMGN STOCK NEWS

Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.

Amgen Inc. (NASDAQ: AMGN) is a leading American multinational biopharmaceutical company, established in 1980 and headquartered in Thousand Oaks, California. As one of the largest independent biotechnology companies globally, Amgen specializes in discovering, developing, manufacturing, and delivering innovative human therapeutics. The company focuses on areas of high unmet medical need and leverages its expertise in advanced human genetics to develop solutions that dramatically improve people's lives.

Amgen's portfolio includes a range of flagship drugs such as red blood cell boosters Epogen and Aranesp, immune system enhancers Neupogen and Neulasta, and treatments for inflammatory diseases like Enbrel and Otezla. Additionally, the company has a strong presence in the oncology sector with products like Vectibix, Prolia, Evenity, and Kyprolis. Notably, the acquisition of Onyx Pharmaceuticals bolstered Amgen's oncology portfolio.

Recent launches include innovative therapies such as Repatha for cholesterol management, Aimovig for migraines, Lumakras for lung cancer, and Tezspire for asthma. In 2023, Amgen's acquisition of Horizon Therapeutics introduced several rare-disease drugs to its portfolio, including Tepezza for thyroid eye disease. Amgen also continues to expand its biosimilar portfolio, reinforcing its commitment to making advanced treatments more accessible.

Amgen's financial health is robust, with significant growth in revenues and product sales. The company's strategic partnerships and acquisitions have continually strengthened its market position. For instance, the recent Phase 3 SPROUT study demonstrated the efficacy and safety of Otezla in pediatric patients, highlighting Amgen's ongoing commitment to addressing various health needs. Furthermore, the company’s dedication to innovation is evident from its extensive pipeline of investigational drugs targeting various conditions.

Amgen has been acknowledged for its workplace culture and environmental initiatives, being named one of

Rhea-AI Summary
Amgen (NASDAQ:AMGN) is set to report its fourth quarter and full year 2023 financial results on February 6, 2024, followed by a conference call with the investment community. The live audio of the call will be broadcast over the internet and archived for replay for at least 90 days after the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.42%
Tags
-
Rhea-AI Summary
A study published in Nature Structural & Molecular Biology by deCODE genetics, a subsidiary of Amgen, revealed that a low-frequency missense variant in the SYCE2 gene increases the risk of pregnancy loss by 22%. The study involved over 114 thousand women from multiple countries and demonstrated that the variant affects recombination, potentially contributing to pregnancy loss. The findings highlight the impact of genetic variants on pregnancy outcomes and provide valuable insights into the biology behind pregnancy losses.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.54%
Tags
none
-
Rhea-AI Summary
Generate:Biomedicines (GB) Announces Clinical Pipeline Advancements and AI Platform Progress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
AI
Rhea-AI Summary
Amgen (AMGN) to Present at 2024 J.P. Morgan Healthcare Conference with Chairman and CEO Robert A. Bradway. Webcast to be Available for Replay for 90 Days
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
conferences
-
Rhea-AI Summary
Amgen (AMGN) receives a Complete Response Letter from the FDA for LUMAKRAS, confirming the dosing at 960 mg once-daily for patients with KRAS G12C-mutated NSCLC under accelerated approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
-
Rhea-AI Summary
Amgen (NASDAQ:AMGN) announced two changes to its senior leadership team, appointing James Bradner, M.D., as executive vice president of Research and Development, and chief scientific officer, and naming David M. Reese, M.D., as executive vice president and chief technology officer. These changes underscore the company's commitment to ongoing scientific and technological innovation, reflecting the rapid convergence of 'biotech' and 'tech' to unlock the next frontier of innovation in biotechnology. Bradner will be responsible for advancing Amgen's pipeline, including potential first-in-class medicines in all stages of development, across Amgen's four therapeutic areas of focus. Reese, on the other hand, will be responsible for accelerating the use of technology and AI across all facets of the organization.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
News
Rhea-AI Summary
Amgen (NASDAQ:AMGN) continues its sponsorship of the Irish Open following the acquisition of Horizon Therapeutics plc, with the 2024 Amgen Irish Open taking place at the Royal County Down Golf Club in Northern Ireland from Sept. 11-15, 2024. The company also becomes a partner to the KPMG Women's Irish Open. Irish professional golfers Shane Lowry, Pádraig Harrington, Séamus Power, and Brendan Lawlor will now become Amgen golf ambassadors. Amgen's chairman and CEO, Robert A. Bradway, expressed the company's commitment to the Irish community, recognizing the tournament's significant contribution to the Irish economy and national pride. Amgen has a 25-year history in Ireland, employs approximately 1,250 people, and supports various Irish patient organizations and education programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
-
Rhea-AI Summary
Amgen (AMGN) receives Priority Review from the FDA for tarlatamab, a potential first-in-class BiTE therapy for advanced small cell lung cancer (SCLC). The Prescription Drug User Fee Action (PDUFA) date is June 12, 2024. The BLA is based on Phase 2 results from the DeLLphi-301 clinical trial, demonstrating antitumor activity and encouraging survival outcomes. Tarlatamab is also being investigated in multiple other studies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
none
-
Rhea-AI Summary
Amgen (NASDAQ:AMGN) declares a $2.25 per share dividend for Q1 2024, marking the 12th consecutive year of dividend increase. The dividend reflects the company's commitment to innovation and balance sheet improvement.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
dividends
Rhea-AI Summary
Amgen (AMGN) presents new data at the 65th ASH Annual Meeting, showcasing the potential of BLINCYTO, KYPROLIS, and biosimilar eculizumab as treatment options for blood cancer patients. The company continues to advance its innovative hematology medicines, emphasizing the expanding potential of its BiTE molecule, BLINCYTO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.81%
Tags
none

FAQ

What is the current stock price of Amgen (AMGN)?

The current stock price of Amgen (AMGN) is $264.49 as of December 24, 2024.

What is the market cap of Amgen (AMGN)?

The market cap of Amgen (AMGN) is approximately 142.2B.

Amgen Inc

Nasdaq:AMGN

AMGN Rankings

AMGN Stock Data

142.17B
536.09M
0.21%
81.11%
1.82%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
THOUSAND OAKS